EP1039914A4 - Cyclooxygenase-2 inhibition - Google Patents

Cyclooxygenase-2 inhibition

Info

Publication number
EP1039914A4
EP1039914A4 EP98961802A EP98961802A EP1039914A4 EP 1039914 A4 EP1039914 A4 EP 1039914A4 EP 98961802 A EP98961802 A EP 98961802A EP 98961802 A EP98961802 A EP 98961802A EP 1039914 A4 EP1039914 A4 EP 1039914A4
Authority
EP
European Patent Office
Prior art keywords
cyclooxygenase
inhibition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98961802A
Other languages
German (de)
French (fr)
Other versions
EP1039914A1 (en
Inventor
Andrew J Dannenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell Research Foundation Inc
Original Assignee
Cornell Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell Research Foundation Inc filed Critical Cornell Research Foundation Inc
Publication of EP1039914A1 publication Critical patent/EP1039914A1/en
Publication of EP1039914A4 publication Critical patent/EP1039914A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP98961802A 1997-12-17 1998-12-07 Cyclooxygenase-2 inhibition Withdrawn EP1039914A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6995597P 1997-12-17 1997-12-17
US69955P 1997-12-17
PCT/US1998/025206 WO1999030721A1 (en) 1997-12-17 1998-12-07 Cyclooxygenase-2 inhibition

Publications (2)

Publication Number Publication Date
EP1039914A1 EP1039914A1 (en) 2000-10-04
EP1039914A4 true EP1039914A4 (en) 2007-06-27

Family

ID=22092236

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98961802A Withdrawn EP1039914A4 (en) 1997-12-17 1998-12-07 Cyclooxygenase-2 inhibition

Country Status (4)

Country Link
EP (1) EP1039914A4 (en)
AU (1) AU1703799A (en)
CA (1) CA2313049A1 (en)
WO (1) WO1999030721A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2357525A1 (en) * 1999-01-27 2000-08-03 Cornell Research Foundation, Inc. Treating cancers associated with overexpression of her-2/neu
EP1194141B1 (en) * 1999-07-02 2005-08-17 Universitair Medisch Centrum Utrecht Antiviral therapy
US6787573B2 (en) 1999-07-02 2004-09-07 Universiteit Utrecht Antiviral therapy
EP1064940A1 (en) * 1999-07-02 2001-01-03 Universitair Medisch Centrum Utrecht Antiviral therapy
AU4485101A (en) * 2000-03-17 2001-09-24 Universitair Medisch Centrum Utrecht Antiviral therapy
CA2472459A1 (en) * 2002-01-10 2003-07-24 Kong Teck Chong Use of cox-2 inhibitors in combination with antiviral agents for the treatment of papilloma virus infections
AR088463A1 (en) 2011-10-21 2014-06-11 Abbvie Inc METHODS FOR HCV TREATMENT
ES2527544T1 (en) 2011-10-21 2015-01-26 Abbvie Inc. Mono treatment (PSI-7977) or combination with ADF for use in the treatment of HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
WO2017189978A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5436265A (en) * 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
WO1997029776A1 (en) * 1996-02-13 1997-08-21 G.D. Searle & Co. Combinations having immunosuppressive effects, containing cyclooxygenase-2-inhibitors and 5-lipoxygenase inhibitors
WO1997029775A1 (en) * 1996-02-13 1997-08-21 G.D. Searle & Co. Compositions comprising a cyclooxygenase-2 inhibitor and a leukotriene b4 receptor antagonist

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
AU6274896A (en) * 1995-06-06 1996-12-24 Procyte Corporation Stable copper(i) complexes as active therapeutic substances

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5436265A (en) * 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
WO1997029776A1 (en) * 1996-02-13 1997-08-21 G.D. Searle & Co. Combinations having immunosuppressive effects, containing cyclooxygenase-2-inhibitors and 5-lipoxygenase inhibitors
WO1997029775A1 (en) * 1996-02-13 1997-08-21 G.D. Searle & Co. Compositions comprising a cyclooxygenase-2 inhibitor and a leukotriene b4 receptor antagonist

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ANDREONE P ET AL: "INDOMETHACIN ENHANCES SERUM 2'5'-OLIGOADENYLATE SYNTHETASE IN PATIENTS WITH HEPATITIS B AND C VIRUS CHRONIC ACTIVE HEPATITIS", JOURNAL OF HEPATOLOGY, MUNKSGAARD INTERNATIONAL PUBLISHERS, COPENHAGEN, DK, vol. 21, no. 6, 1994, pages 984 - 988, XP009042789, ISSN: 0168-8278 *
ANDREONE P ET AL: "Indomethacin increases 2',5'-oligoadenylate synthetase release by cultured liver tissue of patients with HCV chronic active hepatitis", INTERNATIONAL HEPATOLOGY COMMUNICATIONS 1994 NETHERLANDS, vol. 2, no. 5, 1994, pages 289 - 294, XP002422459, ISSN: 0928-4346 *
ANDREONE P ET AL: "Interferon-[alpha] plus indomethacin combined therapy in HBeAg positive chronic hepatitis B non-responder to a previous IFN[alpha] course: Results of a pilot study", INTERNATIONAL HEPATOLOGY COMMUNICATIONS, ELSEVIER SCIENCE, AMSTERDAM, NL, vol. 5, no. 3, 1996, pages 151 - 159, XP002313973, ISSN: 0928-4346 *
HEINRICH D ET AL: "Treatment of chronic viral hepatitis with acetylsalicylic acid", SCHWEIZERISCHE MEDIZINISCHE WOCHENSCHRIFT, vol. 125, no. 15, 1995, pages 755 - 757, XP008075508, ISSN: 0036-7672 *
NANJI AMIN A ET AL: "Enhanced cyclooxygenase-2 gene expression in alcoholic liver disease in the rat", GASTROENTEROLOGY, vol. 112, no. 3, 1997, pages 943 - 951, XP002422458, ISSN: 0016-5085 *
See also references of WO9930721A1 *

Also Published As

Publication number Publication date
WO1999030721A1 (en) 1999-06-24
EP1039914A1 (en) 2000-10-04
CA2313049A1 (en) 1999-06-24
AU1703799A (en) 1999-07-05

Similar Documents

Publication Publication Date Title
ZA98376B (en) Sulfamide-metalloprotease inhibitors
GB2321641B (en) Sulfamide-metalloprotease inhibitors
EP1039914A4 (en) Cyclooxygenase-2 inhibition
GB9712185D0 (en) Case
GB9704794D0 (en) Fouling inhibition
GB2330775B (en) Target
ZA981062B (en) Herbicidal 3-arylamino-6-trifluoromethyluracils
HU9700115V0 (en) Case
GB9717893D0 (en) Inhibitor
GB9707219D0 (en) Inhibitor
CA80851S (en) Thermomter
CA80910S (en) Aeroglisseur
GB2328763B (en) Self-changing perpetual-calendar
CA80915S (en) Elbow-rest
CA82746S (en) Handleset
CA82333S (en) Remorque
CA82745S (en) Handleset
CA79884S (en) Moniitor
CA81694S (en) Tape-rule
GB9716515D0 (en) Chiropodist aid
GB9705050D0 (en) Handcuffs
HU9700114V0 (en) Case
GB9703335D0 (en) Inhibitors
GB9713709D0 (en) Inhibitors
GB9725783D0 (en) Inhibitors

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000714

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CORNELL RESEARCH FOUNDATION, INC.

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 263/32 20060101ALI20070312BHEP

Ipc: C07D 231/12 20060101ALI20070312BHEP

Ipc: A61K 31/42 20060101ALI20070312BHEP

Ipc: A61K 31/415 20060101ALI20070312BHEP

Ipc: A61K 31/365 20060101AFI20070312BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20070530

17Q First examination report despatched

Effective date: 20071002

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100930